Caris Life Sciences (CAI) Short term Debt (2024 - 2026)

Caris Life Sciences has reported Short term Debt for 3 years, with the latest figure at $178000.0 in Q2 2026.

• On a quarterly basis, Short term Debt rose 87.37% year-over-year to $178000.0 in Q2 2026; TTM through Jun 2026 was $178000.0, a 87.37% increase from a year earlier, with the FY2025 full-year figure at $169000.0, down 99.72% from the prior year.
• Short term Debt was $178000.0 for Q2 2026 at Caris Life Sciences, up from $173000.0 in the prior quarter.
• The five-year high for Short term Debt was $60.1 million in Q4 2024, with the low at $95000.0 in Q2 2025.
• Average Short term Debt over 3 years is $10.1 million, with a median of $171000.0 recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Short term Debt slumped 99.72% in 2025, then surged 87.37% in 2026.
• Over 3 years, Short term Debt stood at $60.1 million in 2024, then plunged by 99.72% to $169000.0 in 2025, then increased by 5.33% to $178000.0 in 2026.
• The last three Short term Debt figures came in at $178000.0 (Q2 2026), $173000.0 (Q1 2026), and $169000.0 (Q4 2025), per Business Quant data.